Validity of prostate health index and percentage of [-2] pro-prostate-specific antigen as novel biomarkers in the diagnosis of prostate cancer: omani tertiary hospitals experience
Oman Medical Journal. 2017; 26 (3): 275-283
en Inglés
| IMEMR
| ID: emr-188544
ABSTRACT
Objectives:
Prostate cancer is the leading cancer in older men. The Ministry of Health Oman Cancer Incidence Registry 2013 lists cancer of the prostate as the first most common cancer in males. Therefore, early detection is important and prostate-specific antigen [PSA] is widely used as an established laboratory test. However, despite its wide use, its value in screening, particularly in asymptomatic males, is controversial when considering the risks and benefits of early detection
Buscar en Google
Índice:
IMEMR (Mediterraneo Oriental)
Asunto principal:
Biopsia
/
Estudios Prospectivos
/
Antígeno Prostático Específico
/
Detección Precoz del Cáncer
/
Clasificación del Tumor
/
Centros de Atención Terciaria
Tipo de estudio:
Estudio de tamizaje
Límite:
Anciano
/
Humanos
/
Masculino
Idioma:
Inglés
Revista:
Oman Med. J.
Año:
2017
Similares
MEDLINE
...
LILACS
LIS